Compare iShares MSCI Germany (DAX) (EWG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Repligen Corporation Common Stock — how do they compare? iShares MSCI Germany (DAX) trades at $40.94 (market cap $1.53B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 7.4× iShares MSCI Germany (DAX)'s market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 55 Days and Repligen Corporation Common Stock for 0 Days on average.
| EWG | RGEN | |
|---|---|---|
Market Cap | $1.53B | $11.31B |
Volume | 1,020,541 | 1,216,919 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $194.57 |
52-Week Low | $38.08 | $102.87 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.20 with a modest 0.59% daily gain, though technical indicators signal a bearish trend with moving averages showing 4 buy versus 9 sell signals. The stock faces resistance at $42 with support at $41. Recent European market focus highlights resilience amid ECB rate hikes and energy price pressures affecting regional equities.
Outlook remains cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on European economic stability, but risks include prolonged inflation and energy market volatility. Stock-specific fundamentals are unavailable, requiring deeper due diligence.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
